Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated with tyrosine kinase inhibitors (TKI) such as sunitinib. It inhibits angiogenic pathways by mainly targeting the receptors of VEGF and PDGF. In ccRCC, angiogenesis is characterized by the inactivation...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dornbusch, Juana, Zacharis, Aristeidis, Meinhardt, Matthias, Erdmann, Kati, Wolff, Ingmar, Froehner, Michael, Wirth, Manfred P., Zastrow, Stefan, Fuessel, Susanne
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2013
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3785463/
https://ncbi.nlm.nih.gov/pubmed/24086736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0076386
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi